Searchable abstracts of presentations at key conferences in endocrinology

ea0027oc5.1 | Oral Communications (RCN CYP Diabetes Session) | BSPED2011

Continuous subcutaneous insulin infusion (CSII) at diagnosis

Potts Louise , Thompson Rebecca , Hindmarsh Peter , Agostini Kirsty

The incidence of type 1 diabetes in children under 5 years is increasing. The insulin requirements, eating regimens and reaction to invasive procedures make this group a challenging cohort to manage on multiple daily injections. NICE Guidance was amended in 2008 to include the option of using CSII at diagnosis in the under 5’s.Seven CSII starts at diagnosis have been done (from 2009 to current). CSII is initiated within 72 h from initial diagnosis, ...

ea0027oc4.1 | Oral Communications 4 | BSPED2011

Ethnicity rather than deprivation impacts on diabetes control and use of treatment regimen

Thompson Rebecca , Agostini Kirsty , Luscombe Jennifer , Potts Louise , Viner Russell , Hindmarsh Peter

Introduction: Delivering an equitable service is one component defining a quality service. Various factors impact on diabetes control including health beliefs and socioeconomic pressures. To determine the role played by ethnicity and/or deprivation we audited access to insulin treatment regimens and overall diabetes control in our clinic population of children and young people with type 1 diabetes mellitus (CYPT1DM).Methods: Three hundred and twenty-five...

ea0059oc2.4 | The best of the best | SFEBES2018

Biochemical analysis of radioiodine uptake enhancement in endocrine cancer

Alshahrani Mohammed , Fletcher Alice , Thornton Caitlin , Brookes Kate , Nieto Hannah , Thompson Rebecca , Read Martin , Boelaert Kristien , McCabe Christopher , Smith Vicki

The most common form of endocrine cancer is differentiated thyroid cancer (DTC). Outcomes of DTC largely depend on radioiodine treatment, which is mediated the sodium-iodide symporter (NIS). However, many tumours exhibit NIS dysregulation, resulting in a poorer prognosis. Since breast cancer can also overexpress NIS, albeit of limited function, radioiodine treatment may be a promising treatment option. Our previous data show that overexpression of the pituitary tumor-transform...

ea0038oc6.5 | Advances in reproduction and signalling | SFEBES2015

Pituitary tumor transforming gene binding factor (PBF): a novel modulator of iodide uptake and target for Src phosphorylation in breast cancer

Poole Vikki , Fletcher Alice , Modasia Bhavika , Sharma Neil , Thompson Rebecca , Imruetaicharoenchoke Waraporn , Read Martin , Boelaert Kristien , Smith Vicki , McCabe Christopher

Although the sodium iodide symporter (NIS) is expressed in 70–80% of breast cancers, only 20–30% is located at the plasma membrane (PM) and therefore functional. Previous work in thyroid cells leads demonstrated that PBF redistributes NIS from the PM into intracellular vesicles, potently reducing radioiodide uptake. We therefore examined whether increased membranous NIS could facilitate radioiodide therapy for breast cancer. Immunofluorescent microscopy revealed co-l...

ea0038fp12 | (1) | SFEBES2015

Characterising the functional significance of the first reported mutations in the pituitary tumor-transforming gene binding factor

Imruetaicharoenchoke Waraporn , Watkins Rachel , Modasia Bhavika , Poole Vikki , Fletcher Alice , Thompson Rebecca , Boelaert Kristien , Smith Vicki , Read Martin , McCabe Christopher

Pituitary tumor-transforming gene binding factor (PBF) is a ubiquitous glycoprotein which is over-expressed in thyroid, breast and other endocrine cancers, and modulates cellular invasion, radioiodine uptake and thyroid hormone efflux. Papillary thyroid cancer patients with high PBF expression show decreased disease-specific survival compared to those with lower expression. PBF expression has recently been correlated with breast cancer metastasis and colon cancer extra-mural v...

ea0050oc3.6 | Obesity, Diabetes Thyroid | SFEBES2017

Identification of novel sodium iodide symporter interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Baker Katie , Alshahrani Mohammed , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodide due to decreased expression and/or plasma membrane localisation of NIS. Radioiodide therapy has been proposed as a viable treatment for breast cancer, but is hampered by low levels of NIS membrane localisation. Currently, the regulation of NIS trafficki...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0050oc3.6 | Obesity, Diabetes Thyroid | SFEBES2017

Identification of novel sodium iodide symporter interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Baker Katie , Alshahrani Mohammed , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodide due to decreased expression and/or plasma membrane localisation of NIS. Radioiodide therapy has been proposed as a viable treatment for breast cancer, but is hampered by low levels of NIS membrane localisation. Currently, the regulation of NIS trafficki...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0065op2.4 | Thyroid | SFEBES2019

The proto-oncogene PBF mediates Src modulation of radioiodine uptake

Alshahrani Mohammed , Fletcher Alice , Thornton Caitlin , Brookes Kate , Nieto Hannah , Thompson Rebecca , Raja Saroop , Read Martin , Boelaert Kristien , McCabe Christopher , Smith Vicki

Successful responses to radioiodine treatment in differentiated thyroid cancer ultimately depend on uptake via the sodium-iodide symporter (NIS). However, many tumors exhibit NIS dysregulation, resulting in a poorer prognosis. Since breast cancer can also overexpress NIS, albeit of limited function, radioiodine treatment may be a promising treatment option. Our previous data show that overexpression of the pituitary tumor-transforming gene-binding factor (PBF) is partially res...